ABSTRACT
In the treatment of patients with secondary progressive multiple sclerosis (MS) interferon-β1b had a significant effect on progression of the expanded disability status scale (EDSS)1. This result could neither be confirmed in another study with the same drug, conducted in slightly older and more disabled American MS patients, nor in a study with interferon-β1a. Some authors conclude, that prescribing interferon-β should be limited to those patients who have had disabling relapses in the past 2 years (reviewed in reference 2). Mitoxantrone was effective in secondary progressive MS, but the use may be limited by cardiotoxicity3.
